Businesses
Here's a look at documents from U.S. and international businesses
Featured Stories
VHB and Drive Engineering Join Forces
WATERTOWN, Massachusetts, Jan. 21 [Category: BizEngineering] -- Vanasse Hangen Brustlin Inc., a provider of transportation planning, engineering, design, land development and environmental services, posted the following news:
* * *
VHB and Drive Engineering Join Forces
*
VHB has officially joined forces with Drive Engineering, a transportation engineering firm recognized for applying technology to improve mobility and traffic operations. The partnership expands VHB's reach and advanced resources to support safer, more efficient transportation systems and deliver greater value for clients across
... Show Full Article
WATERTOWN, Massachusetts, Jan. 21 [Category: BizEngineering] -- Vanasse Hangen Brustlin Inc., a provider of transportation planning, engineering, design, land development and environmental services, posted the following news:
* * *
VHB and Drive Engineering Join Forces
*
VHB has officially joined forces with Drive Engineering, a transportation engineering firm recognized for applying technology to improve mobility and traffic operations. The partnership expands VHB's reach and advanced resources to support safer, more efficient transportation systems and deliver greater value for clients acrossthe East Coast.
Founded in 2010, Drive Engineering has built a strong track record of combining technical precision with advanced tools to enhance safety, streamline traffic operations, and support more efficient transportation systems. Their collaborative approach and responsiveness have made them a trusted partner for public and private clients from planning through construction.
"This partnership reflects VHB's commitment to shaping the future of mobility while growing our presence in key markets like Pennsylvania," said Michael Carragher, Chair and CEO of VHB. "By combining Drive's technology-informed approach with VHB's integrated services, we can accelerate innovation and deliver smarter, more resilient transportation systems for communities across the East Coast."
Drive co-founders Mario Toscano and Allie Slizofski will transition to VHB's team, working closely with VHB leadership across the footprint to advance next-generation solutions that improve how communities move.
"Joining VHB is a tremendous opportunity for our teams and clients," said Mario. "We are excited to tap into VHB's extensive resources and collaborative network while continuing the dependable, detail-oriented delivery our clients expect."
"Our team is ready for this next chapter," added Allie. "We've built strong relationships with our clients, and by integrating with VHB, we can offer expanded services, deliver more tailored solutions, and provide even greater value to our clients and the communities we serve."
Through this acquisition, VHB will both expand into Pennsylvania and strengthen its capabilities in Intelligent Transportation Systems (ITS), traffic operations, and data-informed mobility planning.
By combining talent and resources, the teams are well-positioned to address complex challenges such as congestion management, safety improvements, and system reliability-while also supporting clients in adapting to evolving technologies and future transportation demands.
To learn more about VHB's advanced transportation solutions, contact Joe Pizzurro, VHB's Northeast Regional Manager today.
***
Original text here: https://www.vhb.com/news/drive-engineering-and-vhb/
Garmin Introduces Tactix 8 - Cerakote Edition: Premium Tactical Smartwatch Purpose-Built to Withstand Any Mission
OLATHE, Kansas, Jan. 21 -- Garmin, a global positioning system technology developer for automotive, aviation, marine, outdoor and sport activities and utilities, issued the following news release on Jan. 20, 2026:
* * *
Garmin introduces tactix 8 - Cerakote Edition: Premium tactical smartwatch purpose-built to withstand any mission
Hardened ceramic coating offers long-lasting durability and a unique and rugged look
*
Garmin (NYSE: GRMN) today announced tactix(R) 8 - Cerakote(R) Edition, the ultimate tactical smartwatch fortified for the field with a unique and durable finish. The newest smartwatch
... Show Full Article
OLATHE, Kansas, Jan. 21 -- Garmin, a global positioning system technology developer for automotive, aviation, marine, outdoor and sport activities and utilities, issued the following news release on Jan. 20, 2026:
* * *
Garmin introduces tactix 8 - Cerakote Edition: Premium tactical smartwatch purpose-built to withstand any mission
Hardened ceramic coating offers long-lasting durability and a unique and rugged look
*
Garmin (NYSE: GRMN) today announced tactix(R) 8 - Cerakote(R) Edition, the ultimate tactical smartwatch fortified for the field with a unique and durable finish. The newest smartwatchfeatures a stunning 1.4-inch AMOLED display, titanium bezel, sapphire lens and built-in LED flashlight for after-dark visibility. And with up to 29 days of battery life in smartwatch mode, it's easier to push harder for longer.
Premium finish
Cerakote is a ceramic-polymer composite coating popular for its abrasion, corrosion and chemical resistance properties. The premium coating is sprayed onto each smartwatch, then baked to help cure the coating. This provides a unique look and feel that becomes more refined as the watch is worn--giving it a one-of-a-kind rugged look.
tactix 8 - Cerakote Edition boasts a 51mm case and is available in two different Cerakote coatings: slate gray or olive drab.
Mission ready
Like the tactix 8 smartwatch, the Cerakote Edition includes Garmin's suite of dedicated tactical, performance, navigation and connected features.
* Tactical: Input pack weight using the rucking activity profile; use the jumpmaster activity to track three jump types: HAHO, HALO and Static; view two sets of coordinate systems, such as MGRS and latitude/longitude, on a single data screen with dual-position GPS format; use Stealth Mode to turn off wireless communications but still track distances traveled and biometric data without recording location; compatible with night vision goggles; and use the preloaded Applied Ballistics(R) Ultralight solver to access advanced aiming solutions for long-range marksmanship.
* Performance: Reach new depths with a 40-meter dive rating and support for scuba and apnea dive activities; train like never before with strength training plans, sport-specific workouts and real-time stamina tracking; and use 24/7 health monitoring features like Body Battery(TM) energy monitoring, Pulse Ox1 and advanced sleep and nap detection to gain a better understanding of overall health.
* Navigation: View terrain contour on TopoActive maps; access maps for thousands of golf courses and ski resorts worldwide; navigate straight to a location or waypoint in the worldwide aeronautical database, or choose the "Nearest" function to activate a path to a nearby airport; and get superior positioning accuracy using multi-band GPS with SatIQ(TM) technology and a 3-axis compass, gyroscope and barometric altimeter.
* Connectivity: When paired to a compatible Apple(R) or Android(TM) smartphone, use the built-in speaker and mic to make and take phone calls from the wrist; receive smart notifications; and breeze through checkout lines with Garmin Pay(TM) contactless payments.
Available to purchase on www.garmin.com starting January 23, 2026, tactix 8 - Cerakote Edition has a suggested retail price of $1,599.99. See it on display at the Garmin booth, #10119, during SHOT Show 2026. To learn more, visit www.garmin.com.
Engineered on the inside for life on the outside, Garmin products have revolutionized life for adventurers, athletes, off-road explorers, road warriors and outdoor enthusiasts everywhere. Committed to developing products that enhance experiences, enrich lives and help provide peace of mind, Garmin believes every day is an opportunity to innovate and a chance to beat yesterday. Visit the Garmin Newsroom, email our media team, connect with @garminoutdoor on social, or follow our blog.
* * *
1/ This is not a medical device and is not intended for use in the diagnosis or monitoring of any medical condition; see Garmin.com/ataccuracy. Pulse Ox not available in all countries.
* * *
About Garmin International, Inc.
Garmin International, Inc. is a subsidiary of Garmin Ltd. (NYSE: GRMN). Garmin Ltd. is incorporated in Switzerland, and its principal subsidiaries are located in the United States, Taiwan and the United Kingdom. Garmin and tactix are registered trademarks and Body Battery, SatIQ and Garmin Pay are trademarks of Garmin Ltd. or its subsidiaries. Cerakote is a trademark of NIC Industries. Apple is a trademark of Apple Inc., registered in the U.S. and other countries. Android is a trademark of Google LLC. All other brands, product names, company names, trademarks and service marks are the properties of their respective owners. All rights reserved.
* * *
Notice on Forward-Looking Statements
This release includes forward-looking statements regarding Garmin Ltd. and its business. Such statements are based on management's current expectations. The forward-looking events and circumstances discussed in this release may not occur and actual results could differ materially as a result of known and unknown risk factors and uncertainties affecting Garmin, including, but not limited to, the risk factors listed in the Annual Report on Form 10-K for the year ended December 28, 2024, filed by Garmin with the Securities and Exchange Commission (Commission file number 0-31983), and the Quarterly Report on Form 10-Q for the quarter ended September 26, 2025 filed by Garmin with the Securities and Exchange Commission (Commission file number 001-41118). Copies of such Form 10-K and Form 10-Q are available at https://www.garmin.com/en-US/investors/sec/. No forward-looking statement can be guaranteed. Forward-looking statements speak only as of the date on which they are made and Garmin undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
* * *
Original text here: https://www.garmin.com/en-US/newsroom/press-release/outdoor/garmin-introduces-tactix-8-cerakote-edition-a-premium-tactical-smartwatch-purpose-built-to-withstand-any-mission/
[Category: BizElectronic Products]
GSK, Pfizer and Shionogi Agree on Changes to ViiV Healthcare Shareholding
LONDON, England, Jan. 21 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Jan. 20, 2026:
* * *
GSK, Pfizer and Shionogi agree on changes to ViiV Healthcare shareholding
* Following Pfizer's exit, Shionogi's holding increases to 21.7%, with GSK maintaining 78.3% majority share
* Deal simplifies ViiV Healthcare's shareholder structure.
*
GSK plc (LSE/NYSE: GSK) ("GSK"), and Shionogi & Co., Ltd (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D) ("Shionogi") today announced that they have reached agreement together with
... Show Full Article
LONDON, England, Jan. 21 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Jan. 20, 2026:
* * *
GSK, Pfizer and Shionogi agree on changes to ViiV Healthcare shareholding
* Following Pfizer's exit, Shionogi's holding increases to 21.7%, with GSK maintaining 78.3% majority share
* Deal simplifies ViiV Healthcare's shareholder structure.
*
GSK plc (LSE/NYSE: GSK) ("GSK"), and Shionogi & Co., Ltd (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D) ("Shionogi") today announced that they have reached agreement together withPfizer Inc. (NYSE: PFE) ("Pfizer") for the 11.7% economic interest in ViiV Healthcare Limited ("ViiV Healthcare") currently held by Pfizer to be replaced with an investment by Shionogi. As a result of this transaction, Shionogi will increase its economic interest in ViiV Healthcare to 21.7%. GSK will maintain its 78.3% majority owned economic interest. Shionogi will continue to have one Director position on the ViiV Healthcare Board, and will be represented by Dr John Keller who has been a Director of ViiV Healthcare since 2012.
Under the terms of the agreement, ViiV Healthcare will issue new shares to Shionogi for consideration of $2.125 bn and cancel Pfizer's holding in ViiV Healthcare. Pfizer will receive $1.875 bn and GSK will receive a special dividend of $0.250 bn (payable in GBP).
ViiV Healthcare, the global specialist HIV company, is dedicated to delivering advances in treatment and care for people living with HIV and for people who could benefit from HIV prevention. .
David Redfern, Chair of ViiV Healthcare said: "This agreement simplifies ViiV's shareholder structure and we look forward to continuing our highly successful collaboration with Shionogi to advance ViiV's pipeline and portfolio of long-acting injectable HIV treatment and prevention medicines. GSK would also like to thank Pfizer for its longstanding partnership in the development of ViiV since its establishment in 2009."
John Keller, Ph.D., Director of the Board, Senior Vice President, R&D Supervisory Unit at Shionogi said: "Shionogi is dedicated to addressing major infectious diseases, with HIV being one of our most important focus areas, as reflected by our role in the discovery of the innovative integrase inhibitors dolutegravir and cabotegravir. Our ongoing HIV research continues to contribute to ViiV's pipeline through licensing agreements, as is the case for the third-generation integrase inhibitor S-395598/VH 4524184. We are delighted to further deepen our strategic partnership with GSK and ViiV through this agreement, redoubling our commitment and participation in improving the lives of people living with or affected by HIV."
Financial and Regulatory Considerations
Completion of the transaction is subject to certain regulatory clearances in relevant markets, and is expected to occur during the first quarter of 2026.
On completion, GSK will extinguish the Pfizer put option liability through retained earnings. The liability will be remeasured immediately prior to completion, on the same methodology as at 31 December 2025, with any fair value change in the liability recognised as an adjusting item through other operating income.
* * *
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.
* * *
About Shionogi
Shionogi & Co., Ltd. is a leading global research-driven pharmaceutical company dedicated to bringing benefits to patients based on its corporate philosophy of "supplying the best possible medicine to protect the health and well-being of the patients we serve." Shionogi has discovered and developed novel antibiotics, medicines for HIV and influenza, and currently markets medicines for infectious diseases and central nervous system disorders. For more information, visit https://www.shionogi.com/global/en.
* * *
About ViiV Healthcare
ViiV Healthcare is a global specialist HIV company established in November 2009 by GSK (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who could benefit from HIV prevention. Shionogi became a ViiV shareholder in October 2012. The company's aims are to take a deeper and broader interest in HIV and AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV.
For more information on the company, its management, portfolio, pipeline, and commitment, please visit viivhealthcare.com.
* * *
Forward-Looking Statements
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include, but are not limited to, the completion of the transaction on anticipated terms and timing, including obtaining antitrust and other regulatory approvals and clearances in a timely manner or otherwise, and the satisfaction of other conditions to the completion of the transaction. These risks and uncertainties particularly apply with respect to transaction-related forward-looking statements. GSK and Shionogi disclaim any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
* * *
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024, and GSK's Q3 Results for 2025.
* * *
Original text here: https://www.gsk.com/en-gb/media/press-releases/gsk-pfizer-and-shionogi-agree-on-changes-to-viiv-healthcare-shareholding/
[Category: BizPharmaceuticals]
GSK Enters Agreement to Acquire RAPT Therapeutics
LONDON, England, Jan. 21 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Jan. 20, 2026:
* * *
GSK enters agreement to acquire RAPT Therapeutics
* Acquisition includes ozureprubart, a potentially best-in-class anti-IgE antibody, in development for prophylactic protection against food allergens
* Ozureprubart offers potential to protect against food allergy reactions with less frequent dosing compared to existing standard-of-care therapy
* Food allergies are increasing with significant unmet need and serious health risks
* Acquisition adds
... Show Full Article
LONDON, England, Jan. 21 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Jan. 20, 2026:
* * *
GSK enters agreement to acquire RAPT Therapeutics
* Acquisition includes ozureprubart, a potentially best-in-class anti-IgE antibody, in development for prophylactic protection against food allergens
* Ozureprubart offers potential to protect against food allergy reactions with less frequent dosing compared to existing standard-of-care therapy
* Food allergies are increasing with significant unmet need and serious health risks
* Acquisition addsto Respiratory, Immunology & Inflammation pipeline
*
GSK plc (LSE/NYSE: GSK) today announced that it has entered a definitive agreement to acquire RAPT Therapeutics ("RAPT") (NASDAQ: RAPT), a California-based, clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients living with inflammatory and immunologic diseases. The acquisition includes ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody, currently in phase IIb clinical development for prophylactic protection against food allergens.
IgE is a clinically validated target and is the only approved systemic therapy shown to protect patients from a harmful allergic and inflammatory immune response. Around 94% of severe food allergies are caused by IgE-mediated reactions./1
Current anti-IgE treatment for food allergy involves injections every 2 to 4 weeks, which can be a significant burden, particularly since most patients are children. Ozureprubart's clinical profile offers the potential for less frequent dosing of every 12 weeks, supporting improved compliance and patient outcomes; as well as providing a new option to approximately 25% of patients currently ineligible for existing therapy. Ozureprubart complements GSK's extensive commercial footprint and prescriber base in allergy.
Data from the phase IIb trial (prestIgE) assessing use of ozureprubart as monotherapy is expected in 2027, with phase III trials to be focused on both at-risk adult and paediatric populations. In the US, over 17 million people are diagnosed with food allergies, with more than 1.3 million people suffering severe reactions./2,3,4 This results in more than 3 million patient visits each year to hospital and emergency care./5
Tony Wood, Chief Scientific Officer, GSK said: "The addition of ozureprubart brings another promising new, potential best-in-class treatment to GSK's pipeline. Food allergies cause severe health impacts to patients with existing treatment requiring injections as frequently as every 2 weeks. Ozureprubart offers the opportunity to bring sustained protection to patients with dosing every 12 weeks, and is consistent with our approach to acquire assets that address validated targets and where there is clear unmet medical need."
Brian Wong, President & Chief Executive Officer, RAPT Therapeutics, said: "We are excited to enter into this agreement with GSK, which offers an attractive path forward for our programs, particularly the opportunity we envision for ozureprubart in food allergy. This transaction has the potential to provide access to the global development and commercialisation capabilities, resources and infrastructure that GSK has to offer and ultimately bring added value to our pipeline, patients and stockholders."
Financial considerations
Under the terms of the agreement, GSK will pay RAPT Therapeutics shareholders $58.00 per share at closing for an estimated aggregate equity value of $2.2 billion. Net of cash acquired, GSK's estimated upfront investment is $1.9 billion.
The transaction gives GSK the global rights to the ozureprubart programme, excluding mainland China, Macau, Taiwan and Hong Kong. GSK will also be responsible for success-based milestone and royalty payments for ozureprubart owed to RAPT's partner, Shanghai Jeyou Pharmaceutical Co., Ltd.
Under the terms of the agreement, GSK's subsidiary is obligated to commence a tender offer to acquire all outstanding shares of RAPT common stock for $58.00 per share in cash within 10 business days of signing. The transaction is subject to customary closing conditions, including the tender of a majority of RAPT's outstanding shares of common stock in the tender offer and expiration or termination of the applicable waiting period under the under the Hart-Scott-Rodino Act in the US. Promptly following the closing of the tender offer, GSK will acquire any shares of RAPT that are not tendered in the tender offer through a second-step merger under Delaware law at the tender offer price. GSK will account for the transaction as a business combination.
The transaction is expected to close in the first quarter of 2026.
Advisors
Evercore is acting as exclusive financial advisor and A&O Shearman is serving as legal counsel to GSK in connection with the transaction. J.P. Morgan Securities LLC is acting as exclusive financial advisor and Cooley LLP is serving as legal counsel to RAPT Therapeutics.
Additional information
This press announcement is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer or a recommendation to sell securities, nor is it a substitute for the tender offer materials that GSK,
GlaxoSmithKline LLC ("GSK LLC") and its wholly-owned subsidiary, Redrose Acquisition Co. will file with the Securities and Exchange Commission (the "SEC"). The tender offer for the outstanding shares of RAPT Therapeutics common stock described in this press announcement has not commenced. At the time the tender offer is commenced, GSK, GSK LLC and Redrose Acquisition Co. will file, or will cause to be filed, a Schedule TO Tender Offer Statement with the SEC, and, thereafter, RAPT Therapeutics will file a Schedule 14D-9 Solicitation/Recommendation Statement with the SEC, in each case with respect to the tender offer. The Schedule TO Tender Offer Statement (including an offer to purchase, a related letter of transmittal and other offer documents) and the Schedule 14D-9 Solicitation/Recommendation Statement will contain important information that should be read carefully before any decision is made with respect to the tender offer. Those materials (once they become available) will be made available to RAPT Therapeutics stockholders at no expense to them by the information agent for the tender offer, which will be announced. In addition, those materials and all other documents filed by or caused to be filed by RAPT Therapeutics or GSK with the SEC will be available at no charge on the SEC's website at www.sec.gov. In addition to the Schedule 14D-9 Solicitation/Recommendation Statement and Schedule TO Offer Statement (once each becomes available), RAPT Therapeutics and GSK file or furnish, as applicable, annual, quarterly and current reports and other information with the SEC. You may read and copy any reports or other information filed by RAPT Therapeutics at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-0330 for further information on the public reference room. RAPT Therapeutics and GSK filings with the SEC are also available to the public from commercial document-retrieval services and at the SEC's website at www.sec.gov.
* * *
About food allergies
In the US, over 17 million people are diagnosed with food allergies, with more than 1.3 million people suffering severe reactions.2,3,4 Notably, 65% of severe food allergy patients are children and adolescents.1 This results in more than 3 million patient visits each year to hospital and emergency care.5 Disease burden is amplified by the frequency and complexity of allergic reactions, which can escalate to anaphylaxis, emergency care and impact a patient's wellbeing and participation in social activities. Collectively, food allergies cost US families an estimated $33 billion in 2024, underscoring the need for more effective and durable therapies.5
* * *
About RAPT Therapeutics
RAPT Therapeutics is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunologic diseases. Utilizing deep and proprietary expertise in immunology, RAPT develops novel molecules that are designed to modulate the critical immune responses underlying these diseases.
* * *
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
* * *
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for the year ended December 31, 2024. This communication includes forward-looking statements related to RAPT Therapeutics, ozureprubart and the acquisition of RAPT Therapeutics by GSK that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief or current expectation of RAPT Therapeutics and members of its senior management team and can typically be identified by words such as "believe," "expect," "estimate," "predict," "target," "potential," "likely," "continue," "ongoing," "could," "should," "intend," "may," "might," "plan," "seek," "anticipate," "project" and similar expressions, as well as variations or negatives of these words. Forward-looking statements include, without limitation, statements regarding the business combination, similar transactions, prospective performance, future plans, events, expectations, performance, objectives and opportunities and the outlook for RAPT Therapeutics' business; the commercial success of RAPT Therapeutics' products; the anticipated timing of clinical data and regulatory filings or approvals relating to products; the possibility of favourable or unfavourable results from clinical trials; the anticipated benefits of the acquisition; filings and approvals relating to the transaction; the expected timing of the completion of the transaction; the parties' ability to complete the transaction; and the accuracy of any assumptions underlying any of the foregoing. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties. Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include: uncertainties as to the timing of the tender offer and completion of the merger; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that RAPT Therapeutics stockholders may not tender into the offer a majority of the shares of common stock outstanding at the time of the expiration of the offer or that required regulatory approvals may not be obtained or are obtained subject to conditions that are not anticipated; the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement; the failure to realize anticipated benefits of the proposed acquisition when expected or at all; potential adverse reactions or changes to business relationships resulting from the proposed acquisition, including the effect of the announcement, pendency or consummation of the acquisition on the ability of RAPT Therapeutics to retain and hire key personnel or maintain key vendor, supplier or partner relationships; risks that the proposed acquisition disrupts the current plans and operations of RAPT Therapeutics; transaction costs; risks associated with potential litigation or regulatory actions related to the transaction; and other risks and uncertainties described from time to time in documents filed with the SEC by RAPT Therapeutics, including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, as well as the Schedule 14D-9 to be filed by RAPT Therapeutics, or in GSK's Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC by GSK, as well as the Schedule TO to be filed by GSK. All forward- looking statements are based on information currently available to GSK and RAPT Therapeutics, and neither GSK nor RAPT Therapeutics assumes any obligation to update any forward-looking statements.
* * *
References
1./ GSK Epi assessment based on MarketScan and Optum claims database
2./ Warren CM, Aktas ON, Manalo LJ, Bartell TR, Gupta RS. The epidemiology of multifood allergy in the United States: a population-based study. Ann Allergy Asthma Immunol. 2023;130(5):637-648.e5.
3./ US Census Bureau. Age and Sex, American Community Survey, ACS 1-Year Estimates Subject Tables, Table S0101, 2022. Accessed 9 January, 2026. https://data.census.gov/table/ACSST1Y2022.S0101.
4./ MarketScan's overall prevalence, and Optum's age-stratified (<18; 18+) and overall prevalence. Severe FA defined as patients with ER/inpatient visit or under specialist care.
5./ FARE Food Allergy Facts and Statistics for the US (April 2024).
* * *
Original text here: https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-acquire-rapt-therapeutics/
[Category: BizPharmaceuticals]
Five Leading Travel Technology Providers Choose SabreMosaic Travel Marketplace to Unlock Access to Over 40 NDC Airlines
SOUTHLAKE, Texas, Jan. 21 -- Sabre, a travel technology company, issued the following news release on Jan. 19, 2026:
* * *
Five Leading Travel Technology Providers Choose SabreMosaic(TM) Travel Marketplace to Unlock Access to Over 40 NDC Airlines
Sabre Corporation (NASDAQ: SABR), a leading global travel technology company, today announced that five travel technology providers--Lleego, Vibe, TPConnects, Ypsilon.net, and Mesh--have chosen to connect to SabreMosaic(TM) Travel Marketplace, unlocking access for their connected leisure, corporate, and online travel sellers to shop, book, and fully
... Show Full Article
SOUTHLAKE, Texas, Jan. 21 -- Sabre, a travel technology company, issued the following news release on Jan. 19, 2026:
* * *
Five Leading Travel Technology Providers Choose SabreMosaic(TM) Travel Marketplace to Unlock Access to Over 40 NDC Airlines
Sabre Corporation (NASDAQ: SABR), a leading global travel technology company, today announced that five travel technology providers--Lleego, Vibe, TPConnects, Ypsilon.net, and Mesh--have chosen to connect to SabreMosaic(TM) Travel Marketplace, unlocking access for their connected leisure, corporate, and online travel sellers to shop, book, and fullyservice New Distribution Capability (NDC) content from 42 airlines within their existing workflows.
By selecting SabreMosaic Travel Marketplace, these companies are responding to the growing demand for unified access to modern airline content, including NDC. Sabre now offers the industry's broadest NDC airline coverage, with recent global launches including British Airways, Iberia, Air France, KLM, Lufthansa), Qatar Airways, Emirates, and a pipeline of more than 60 additional carriers coming online. This breadth allows agencies and corporates using these five leading travel technology providers to access NDC offers, continuous pricing, bundled fares, and new ancillaries in the same environment as traditional and low-cost carrier content, without the need for separate direct connections or custom integrations for each airline. Each of the five providers will enable SabreMosaic Travel Marketplace content progressively, following their own roadmaps, creating flexibility while opening the pathway for future activations.
The technical foundation for this expansion is Sabre's structured approach to NDC integrations, which standardizes airline-specific nuances. Rather than building and maintaining one-off connections to individual airlines, these providers use Sabre's harmonized APIs to present multi-source content, including NDC, consistently. The capabilities span end-to-end workflows, and enable execution of all post-booking actions, cancellation, void, refund, exchange, seat selection, and ancillary management, regardless of the airline.
For agencies and buyers, the result is a significant reduction in manual workarounds, fewer errors, and faster onboarding of new airline content. NDC content sits alongside traditional and low-cost carrier options in unified displays, allowing agents to compare options like-for-like and select the offer that best fits traveler needs and program rules. Corporate buyers retain their policy controls and duty-of-care visibility when their online booking tools are powered through Sabre. They also gain access to airline features such as continuous pricing and exclusive promotions without introducing parallel systems or retraining teams.
"Lleego, Vibe, TPConnects, Ypsilon.net, and Mesh have gone beyond connectivity to deliver the book-and-service depth agencies expect," said Miguel Gonzalez, Senior Director Global Commercial Planning, Management Consulting and Partner Solutions at Sabre. "Their customers can use NDC from carriers we've launched across the marketplace, and they can do it inside the same agent and corporate tools they trust today. That is how you scale NDC, pairing coverage leadership with workflows that protect efficiency".
By expanding their NDC connection through Sabre, these partners help agencies and corporates to adopt modern airline content without adding systems. The technical lift shifts from bespoke, airline-by-airline builds to a unified implementation that preserves servicing parity, compliance, and reporting. The result is faster activation, fewer workarounds, and better traveler outcomes.
* * *
Original text here: https://www.sabre.com/insights/releases/five-leading-travel-technology-providers-choose-sabremosaic-travel-marketplace-to-unlock-access-to-over-40-ndc-airlines/
[Category: BizComputer Technology]
FNBO Releases 2026 Outlook: Stay Invested, Stay Diversified, Stay Disciplined
OMAHA, Nebraska, Jan. 21 (TNSrep) -- First National Bank of Omaha, a subsidiary of First National of Nebraska Inc., issued the following news on Jan. 20, 2026:
* * *
FNBO Releases 2026 Outlook: Stay Invested, Stay Diversified, Stay Disciplined
Co-Authored by CIO Rusty Vanneman & SVP Kurt Spieler, Report Examines Market Concentration, AI Productivity, Diversification Opportunities and the Importance of Discipline
*
FNBO (First National Bank of Omaha) today released the FNBO 2026 Outlook: Stay Invested, Stay Diversified, Stay Disciplined (https://www.fnbo.com/insights/wealth/2026/2026-investment-outlook),
... Show Full Article
OMAHA, Nebraska, Jan. 21 (TNSrep) -- First National Bank of Omaha, a subsidiary of First National of Nebraska Inc., issued the following news on Jan. 20, 2026:
* * *
FNBO Releases 2026 Outlook: Stay Invested, Stay Diversified, Stay Disciplined
Co-Authored by CIO Rusty Vanneman & SVP Kurt Spieler, Report Examines Market Concentration, AI Productivity, Diversification Opportunities and the Importance of Discipline
*
FNBO (First National Bank of Omaha) today released the FNBO 2026 Outlook: Stay Invested, Stay Diversified, Stay Disciplined (https://www.fnbo.com/insights/wealth/2026/2026-investment-outlook),offering a comprehensive analysis of the economic, market and behavioral forces shaping investment decisions in the year ahead.
The 2026 Outlook underscores a planned leadership transition at FNBO Wealth. The report is co-authored by Senior Vice President, Investment Management Kurt Spieler and Rusty Vanneman, who will succeed Spieler in the CIO role, as announced earlier this month.
"Each year, we have shared market and economic data alongside our views on the investment landscape. As this year's Outlook also marks a personal transition, our focus remains on understanding investment goals and guiding clients to the appropriate asset allocation for meeting those objectives," said Kurt Spieler, Senior Vice President, Investment Management, FNBO.
Key themes and perspectives include:
* Stay Invested: Market volatility can test an investor's resolve and lead to emotional decisions, but investors can be rewarded for maintaining a disciplined approach, a long-term time horizon and a prudent rebalancing plan.
* Economic Growth and Productivity: Historically, economic activity is driven by the growth in the number of workers and the increase in real output per worker, or productivity. As fewer people enter the workforce, growth in the 2020s is increasingly derived from productivity, specifically from a focus on corporate efficiency and AI benefits.
* Labor Market and Inflation Pressures: Total employment growth has decelerated, and while the unemployment rate remains relatively low, it has been consistently rising. Inflation and affordability remain a concern, while consumer spending is being driven largely by high-net-worth households that have yet to meaningfully pull back.
* Market Concentration and Valuations: U.S. large-cap performance has been dominated by a narrow group of mega-cap technology stocks, increasing market concentration and portfolio risk. At the same time, stock market valuations have pushed to the highest levels of this century, increasing vulnerability when market leadership shifts.
* Diversification Opportunities: Market leadership rotates, making diversification across regions and asset classes essential. Valuations are more attractive outside the largest U.S. companies, with small- and mid-cap stocks trading at their largest discount in decades, while international equity valuations remain close to long-term averages.
* Bonds and Alternatives: Higher absolute yields make Treasury bonds more attractive than they have been over the last decade and help minimize downside risk. In this environment, diversifying from traditional assets may improve portfolio resilience.
* Stay Disciplined: Long-term asset allocation and sticking to the plan in periods of volatility can drive investor returns. Maintaining a disciplined approach and prudent rebalancing helps manage behavioral biases and positions portfolios to meet return objectives
"This year's Outlook focuses on themes that have consistently guided FNBO's investment thinking: 'Stay Invested, Stay Diversified, Stay Disciplined.' These principles reflect a long-term approach that prioritizes logic and data over emotional reactions, and helps position portfolios to navigate changing market conditions," said Rusty Vanneman, Chief Investment Officer, FNBO.
To read the full text of the FNBO 2026 Outlook--visit here (https://www.fnbo.com/insights/wealth/2026/2026-investment-outlook).
* * *
About FNBO
FNBO (First National Bank of Omaha), a subsidiary of First National of Nebraska, Inc. (FNNI), is one of the largest privately held banks in the US and has been in business for more than 165 years. FNNI and its affiliates have nearly $35 billion in assets and 5,000 employees. Primary banking offices are located in Nebraska, Colorado, Illinois, Iowa, Kansas, Missouri, South Dakota, Texas and Wyoming, providing personal and business banking, mortgage, payment solutions, wealth management and more. Founded in 1857, FNBO has maintained its commitment to customers and helping build strong communities. Learn more at FNBO.com and connect on Facebook, X and Instagram. Member FDIC. Equal Housing Lender.
* * *
Original text here: https://www.fnbo.com/insights/newsroom/2026/fnbo-releases-2026-investment-outlook
[Category: BizFinancial Services]
Boston Consulting Group: Two-Thirds of Top Marketing Leaders Expect a High Level of AI-Driven Disruption to Consumer Behavior
BOSTON, Massachusetts, Jan. 21 (TNSrpt) -- Boston Consulting Group, a management consulting firm, presented the following news release:
* * *
Two-Thirds of Top Marketing Leaders Expect a High Level of AI-Driven Disruption to Consumer Behavior
* New Consumer AI Disruption Index from BCG and Moloco Reveals the Most Exposed Industries
* News, Travel, Auto Marketplaces, and Retail Are the Industries Most at Risk for Disruption
* Auto OEMs, Fintech, Financial Services, Media/Streaming and Social Are at Lowest Risk
*
AI is rewiring the digital economy in real time, forcing marketers to decode
... Show Full Article
BOSTON, Massachusetts, Jan. 21 (TNSrpt) -- Boston Consulting Group, a management consulting firm, presented the following news release:
* * *
Two-Thirds of Top Marketing Leaders Expect a High Level of AI-Driven Disruption to Consumer Behavior
* New Consumer AI Disruption Index from BCG and Moloco Reveals the Most Exposed Industries
* News, Travel, Auto Marketplaces, and Retail Are the Industries Most at Risk for Disruption
* Auto OEMs, Fintech, Financial Services, Media/Streaming and Social Are at Lowest Risk
*
AI is rewiring the digital economy in real time, forcing marketers to decodenew consumer behaviors and rethink their playbooks. In a survey of top marketing leaders, 67% say they expect major disruption to the consumer journey, and nearly all are bracing for meaningful shifts ahead.
To understand which industries are most exposed to disruption from consumer-facing large language models and AI assistants, Boston Consulting Group (BCG) and Moloco--a leader in AI performance advertising--have developed the Consumer AI Disruption Index. The joint report assesses 17 consumer-facing verticals in terms of their vulnerability to AI-driven disruption.
These are among the insights in a new report from BCG and Moloco titled Battle for the Interface: Introducing the Consumer AI Disruption Index . The report features findings from a survey of 238 senior marketing leaders from five regions of the world, combined with performance data from more than 3,200 apps with over 200 billion downloads. The data includes anonymized vertical benchmarks from Moloco advertisers such as metrics for retention, user value, and acquisition cost, and from organic and paid traffic sources.
"AI is fundamentally reshaping how consumers interact with brands," said Giorgo Paizanis, a BCG partner and co-author of the report. "Our research shows that to win, marketers must build defensibility on three fronts: discovery, service, and customer relationships. Those who move early can turn this disruption into a durable advantage, recasting AI from a threat into a new channel for growth."
Introducing the BCG x Moloco Consumer AI Disruption Index
The Consumer AI Disruption Index is a qualitative and quantitative study that maps 17 consumer-facing verticals along two axes: risk of AI-driven disruption and strength of customer relationships.
The index reveals four archetypes of readiness:
* Breached (for example, travel, retail, and news): These verticals face high disruption risk as AI compresses discovery and comparison. Their survival depends on strengthening customer relationships and embedding AI within their own platforms.
* Undefended (for example, gaming, dating, and GenAI): These verticals face moderate disruption but have weak brand ties. Their challenge is to convert transactional relationships into durable loyalty through personalization and AI partnerships.
* Secured (for example, fintech, financial services, and media/streaming): These verticals are at lowest risk for disruption, with inherent trust and regulatory moats. Their opportunity lies in using AI to drive efficiency and hyperpersonalized engagement.
* Contested (for example, productivity): These verticals combine strong customer equity with some exposure to service disruption risk, putting them in a strong position to define how AI integrates into their verticals.
"As consumers move from the world of search to the world of answers, we're seeing a behavioral shift that risks disrupting digital brands across a broad range of industries," said Paul D'Arcy, Moloco chief marketing officer and a co-author of the report. "The companies that will thrive in this new age of AI will focus on longer-term customer relationships, owned digital surfaces like apps, and strategies that strengthen brand and loyalty."
* * *
About Moloco
Moloco is the AI performance advertising company, empowering businesses to drive growth and monetization through advertising. Moloco's planet-scale AI systems are the foundation of Moloco's three distinct product lines. Moloco Ads is an AI-powered advertising platform for mobile app marketers built to drive real business outcomes in today's mobile-first world. Moloco Commerce Media and Streaming Monetization solutions enable retailers, marketplaces, and streaming platforms to build revenue-generating ad businesses that balance viewer experience and advertiser performance. Moloco was founded in 2013 by a team of machine learning engineers and has offices throughout the US, the UK, Germany, Korea, China, India, Japan, and Singapore.
* * *
About Boston Consulting Group
Boston Consulting Group partners with leaders in business and society to tackle their most important challenges and capture their greatest opportunities. BCG was the pioneer in business strategy when it was founded in 1963. Today, we work closely with clients to embrace a transformational approach aimed at benefiting all stakeholders--empowering organizations to grow, build sustainable competitive advantage, and drive positive societal impact.
Our diverse, global teams bring deep industry and functional expertise and a range of perspectives that question the status quo and spark change. BCG delivers solutions through leading-edge management consulting, technology and design, and corporate and digital ventures. We work in a uniquely collaborative model across the firm and throughout all levels of the client organization, fueled by the goal of helping our clients thrive and enabling them to make the world a better place.
* * *
REPORT: https://web-assets.bcg.com/ca/45/1264a432453d90b7b3ab86ea3cbd/battle-for-the-interface.pdf
* * *
Original text here: https://www.bcg.com/press/21january2026-marketing-leaders-expect-ai-driven-disruption-consumer-behavior
[Category: BizConsulting]
